Patients who maintain muscle mass during GLP-1 therapy lose more total fat, see better body composition results, and are significantly less likely to regain weight after discontinuing the medication.
Medications prescribed included, metformin extended release 80% (n=32), topiramate 32.5% (n=13), bupropion 32.5% (n=13), phentermine 20% (n=8), and naltrexone 2.5% (n=1)
Second, the study was powered solely based on anticipated changes in GLP-1 levels and was not designed to detect correlations between GLP-1 or GIP and weight regain (WR), nor to evaluate the differential effects of semaglutide across hormonal subgroups
If validated, future trials may require fewer surveysand cause fewer crashes
Do not adjust semaglutide dosing or add glutathione without medical guidance, even if online sources suggest the combination is risk-free
Appetite regulation becomes more apparent